Chapters Transcript Video Advances in Lung Cancer Care Targeted Therapies, Robotic Surgery & Beyond Welcome to Baptist Health Doc to Doc, a podcast bringing together leading experts from Baptist Health South Florida to discuss clinical innovation and advances in patient care. Today we are discussing lung cancer and how our understanding of the disease is reshaping the way we diagnose and treat patients. While smoking remains a major risk factor, lung cancer is increasingly challenging traditional assumptions. About who develops the disease and which treatments may offer the greatest benefit from early detection and molecular profiling to targeted therapies and robotic assisted surgery, physicians have more tools than ever to personalize care. We'll explore how these developments are influencing clinical decision making, the importance of multidisciplinary collaboration, and what's next in lung cancer treatment. Welcome to Baptist Health Doctor Doc, a podcast built for innovation and collaboration by physicians for physicians. Hello, I'm Doctor Bruna Pellini, Chief of Thoracic Medical Oncology at Baptist Health Herbert Wertheim Cancer Institute. Joining me is my colleague, Doctor Ian Bostok, thoracic surgeon at the Herbert Wertheim Cancer Institute. Welcome, Doctor Vostok. Thank you. It's great to be here. So, uh, today, I'm gonna be asking you a few questions, uh, and I really wanna understand your take on those points that we're gonna be going over today. So when we think about lung cancer, we often picture an older patient with a significant smoking history, but that's not always the patient we're seeing clinical clinical practice today, particularly here in South Florida. So we're seeing a lot of young patients, Hispanic patients, and a lot of those individuals, they have different diseases than the traditional non-small cell lung cancer. We are seeing more lung cancer in patients who have never smoked. So Dr. Bostok, are you seeing a similar shift in the patients coming to you for surgical evaluation? That's my first question. And my second question is how is that changing the way you think and we think about who may be at risk for lung cancer? I think we have definitely noticed a Big change over the past, let's call it 20 years in the, in, in, in the patient that presents to our office. I think traditionally, you would have thought you see a lot of patients in uh that are older, most of the time in advanced stages of their disease, so stage 4 lung cancer showing up in your office in the elder, elderly patients in their late 70s or 80s. Now, with all the the the the advances in technology and, and, and just improvements in patient care overall, we're seeing a shift towards an earlier diagnosis, which is allowing us to see patients in a, in an earlier stage of their disease. A lot of this has to do with uh with lung cancer screening, but also in general with, with, with an an an uptake in the use of imaging technology in the community. So lung cancer screening, of course, we would do dedicated CT scans to try to find. The cancer in patients that are at risk of developing lung cancer, but uh there's a big big group of patients that are being diagnosed incidentally. So I'll give you an example. Somebody that has uh an accident and suddenly shows up in an emergency room for something completely unrelated, you know, they, they fell and fractured their rib or something of the sort, and then they had a CT scan of the chest at that time, which may show a small nodule or something in their lungs that warrants further attention. And that triggers a, a bunch of workup that eventually leads to the earlier diagnosis of lung cancer. So these incidental lung nodules now represent a big bulk of the work that we do as well. So that really helps us see patients in the early stage, but also we continue to see those patients in more advanced stages. Mhm. So one point that I want to ask you, we are very lucky that we can diagnose these patients earlier because then we have a chance to cure them. But what about the patients that have never smoked? Is there a way to screen them? What do the guidelines say for the never smoking patients? So the quick answer is no, right? But that doesn't mean that we're not constantly challenging that dogma or that, or, or, or that strategy. So right now as it stands today, the guidance to, to uh for, for a patient to qualify for lung cancer screening are aged more than 50, OK? Um, uh, more than 20 packs per year smoking history or let's call it a significant smoking history, having quit less than 15 years ago, OK? Or, uh, or having some other risk factor for lung cancer that that makes you want to get that, that, that test, OK. So that might, that's how you get kind of like quote unquote insurance approval for a run of the mill lung cancer screening. And what is that? It's a low dose CT scan of the lungs, OK? So it's different than a traditional CT scan. It's a little lower resolution and a little faster to, to obtain a little lower radiation dose, although the radiation dose in general is super low, OK, but it allows us to really better understand what's happening in the lung parenchyma or in the lung tissue. Now if we compare that to a normal chest X-ray, there's really, it's a no-brainer. Chest X-rays really don't work for lung cancer screening. There's a big study that was published in the 90s that, that shows us uh they followed a, a, a, a, a big group of, of our population in the US and they compared lung cancer screening with chest X-rays versus lung cancer screening with CT scans. And CT scans was, were, were incredibly far superior but also led to a reduction in mortality from lung cancer of 20%. From somebody that doesn't practice medicine, 20% doesn't sound much, but for us that dedicate our lives to the treatment of cancer, 20% is the biggest impact we have seen from anything immunotherapy, surgery, chemotherapy. Nothing compares with that 20%. So really early detection is the key. So take home points, early detection saves lives, lung cancer screening saves lives, and X-rays are not enough. So we, you mentioned a little bit about the incidental nodules, and I know you have built our program, so thank you for that. So when a suspicious nodule is identified, the diagnostic workup becomes critical. So how have advances in imaging and minimally invasive diagnostic techniques improved our ability to diagnose and accurately stage lung cancer? Yeah, so there's, there's well established guidance to that, that inform us what to do about different uh lung nodules found incidentally. But the most important thing is to understand 4 characteristics about the nodule, OK? Number one is the size. If a nodule is less than 8 millimeters, most of the time, it just warrants further follow-up, but it's not particularly concerning at that time. I'm not saying it's never lung cancer, I'm just saying at that time, it's not as concerning. So, we basically by size classify them into less than 6 millimeters, mostly benign, 6 to 8 millimeters. Um, warrants further further evaluation may or may not be lung cancer. 8 millimeters high risk of of representing a malignant lesion. That doesn't mean that all of them are malignant lesions, of course, but it just warrants further workup. Um, so when we find these, these nodules, uh, the size can help us really classify as to where to go. Other things that we look for are characteristics within the nodule. So if the nodule is very, very, um, homogeneous or, or, or very round and well defined, then it appears to be less concerning as opposed to uh irregular and speculated. We use that trigger word to say something that appears to be invading the tissue around it, uh, or with some adjacent inflammation, those tend to be more concerning. And then um another one is risk factors that uh that from each individual patient such as uh exposure to tobacco or maybe asbestos or radon, air pollution, other things that, that could um make them higher risk of having lung cancer. And then the third one, which is often not mentioned but is really critical. Is comparison over time. And the reason why I mention it is because when people engage in lung cancer screening, they think, OK, I'm gonna get a CT scan of the, of the, of the lungs and then um then I'm done. If they, if they're clean, I never have to do it again. And you know, it really is like a mammogram. It should be done every year so that we can compare, compare one image. The other. So in, in regards to an incidental lung nodule, if you have an image from a year before or a period of time that we can compare it to, if there's been growth, then we know that that's a lesion to take seriously. If there's stability over time or a lack of change, then we tend to be more reassured. I love that you made this analogy with mammograms because uh we are fortunate that breast cancer cases are detected early, but I wish it's my dream that we have more lung cancer cases that are detected earlier and the importance of screening, you just summarize it beautifully. Now I wanna go back to a couple of points. So you mentioned that there. Differences in size and appearance and risk factors that can determine surveillance versus pursuing a biopsy. So is it fair to say that a larger nodule that is speculated would be the one that you would pursue a surgical evaluation or a biopsy? Yes, for sure. So if we have a nodule that appears concerning just from the characteristics. We mentioned, from a size criteria, usually it's more than 8 millimeters that tends to um to catch our attention for sure. Um, that usually means further workup. So what, what does that workup entail? Usually, if the nodule is more than 8 millimeters, it's within criteria to be able to perform a PET scan, right? So as we explain it to our patients, a PET scan is a CT scan with, with radioactive. Uh, glucose, so that that makes infection, inflammation, or cancer, uh, light up or or or glow up on the, on the scan. We're looking for activity within the nodule but also activity anywhere else just to see maybe there's involvement in the lymph nodes within the chest, in the mediastinum or along the, the lung parenchyma or any activity anywhere else, and this will help us guide our intervention, OK. So, um, we find a lung nodule, we get a PET scan, and that'll help us kind of either solidify our concern or maybe reassure us more. So if we go down the route where the, where the PET scan is showing us activity, then that's a person that I would talk about either doing upfront surgery or doing a biopsy, OK? So nowadays we have very novel ways to, uh, to obtain tissue and to obtain a biopsy, OK. Um, there's two ways of doing it. One of them, which is a more traditional way, is to do a CT guided biopsy or a guided or an, uh, a biopsy that's guided through, um, a tomography imaging from the outside. We bring an under local anesthesia. The interventional radiologist brings a needle from the outside and pokes the area of the nodule, grabs a sample and looks at it under the microscope. This is tried and true. It's been, it's been, um, in, in, uh, used in practice for, for decades. Usually that yields a diagnostic uh certainty of about, let's call it 80 or 90% in the, in the best places, OK? But the location of the nodule really matters. So these are nodules are are usually in the periphery on the or in the outer third of the lung tissue, uh, in, in an area where it's easy to get to with no major vessels or anything concerning, that's usually the perfect case for that. The alternative to doing a CT guided biopsy is to do something called robotic bronchoscopy. So robotic bronchoscopy, a major difference is that it requires an event of general anesthesia, so the patient is completely asleep and we introduce a robotic bronchoscope into the airway, uh, and we drive it over to the area where the lung nodule is. Um, we get to that area using AI generated, um, uh, pathways in the, in the, in the airways, in the, into the lung parenchyma. So what we do is We use the CT scan that we, that we evaluated the patient with, the one that diagnosed the lung nodule, and we loaded it, loaded up into a system that, that kind of analyzes the patient's anatomy and creates a pathway for us. Uh, and then using this bronchoscope, we're able to follow these bread crumbs over to the area of the lung nodule and then we use other different technology to make sure that we are, is, is basically an ultrasound probe to make sure that we're within the nodule or or close to it. So that we can, we can take biopsies. This has allowed us, this technology to, to uh get biopsies on smaller nodules with more certainty but also go to, go after um larger uh more peripheral nodules as well, larger nodules, so it allows us to do a little bit more than the traditional CT guided biopsy which I mentioned before. Uh, this also allows you to use that episode of anesthesia to do something called an endobronchial ultrasound, which is an ultrasound of the airways in which we sample lymph nodes around it that allows us to make sure that we know whether there's any involvement of cancer cells in those in the lymph nodes around the airway, which is critical to be able to understand what type of management to offer the patients. So those two are the main ways of diagnosing things. That being said, um. There's so many more nodules that we're detecting incidentally now in early stages that sometimes when uh when we're having a conversation with patients, a lot of patients if they have a nodule that's, let's say in the periphery or on the outer third of the lung, it looks like it's taking a lot of activity, it's showing a lot of activity on that PET scan. It looks concerning on imaging. Sometimes we can even tell them just from those characteristics like your, this nodule is, is about 80 or 90% likely to be cancer and many patients like to go and go into surgery right then and there. So, if they go into surgery, it's an episode of general anesthesia, of course, and we can use robotic techniques that include 4 small incisions along the chest cavity usually, but we also have another approach and we only use a single incision. To um to go to the area where that nodule is and maybe perform a small wedge resection or a small segmentectomy or taking a small segment of the lung with a margin of normal lung tissue as a as a as both a diagnostic and therapeutic intervention. Very interesting, so to summarize because you gave us a lot of good points, if the nodule is concerning, a PET scan will follow, very important, and then we need to know if the cancer is really just in the lung or elsewhere, so the lymph gland. In between the lungs and inside the lungs are very important, and patients always ask us about anesthesia. So like you described beautifully, there are two procedures that anesthesia is warranted the bronchoscopy that is diagnostic, and also to stage if lymph glands are involved, or the surgical wedge resection or segmentectomy that will lead to a full surgery. Is that a fair summary? Yes, OK, perfect. So now we talked about the fact that Screening has made a significant difference, but like we discussed previously, our current guidelines, they do not include all patient populations that are at risk of developing lung cancer, particularly the never smokers and patients who have not fit the traditional criteria that you beautifully summarized. So once lung cancer is diagnosed, molecular profiling has fundamentally changed how we approach treatment. Allowing us to better understand the biology of each patient's tumor and identify more personalized treatment strategies. So could you explain to us, and I know you lead some of our clinical trials and surgical patients, the importance of this testing even before surgery for us to determine a treatment and surgical plan. Yeah, I mean there's so many different nuances about the decision making. Here, but really the, the, the bottom line should, should, or the, the central message is that we wanna know more about, uh, uh, as, as we wanna know the most characteristics about the tumor before we make a decision about taking it out or treating it. We want to make sure that we characterize, characterize it appropriately so that we can choose the best treatment for each individual. And that's really the key here. We wanna individualize the approach. We have, we have abandoned. The strategy where one size fits all and we're trying to be a lot more diligent about gathering these details to make sure that we're making proper decisions for the patients and that the patients get the best care possible. So that really gets highlighted by, by working in a multidisciplinary environment, right? Working with different people from different disciplines that all want the best for their patients, right, or for our patients and but all bring different skill sets to the table, right? So, Uh, whenever possible, we want to obviously have a tissue diagnosis, knowing what we're dealing with, but we, we want to classify, um, the, the, the characteristics of the tumor a little bit further. So you mentioned biomarker testing, which really In the day today, it's, it means 33 things, OK? 3 tests. We want to know whether there's any PDL1 expression, which is a marker of whether the patient, and then you're gonna maybe bat your eyes at me, but this is how I explain it as a surgeon. Uh, it helps us understand whether a patient is, is likely or not very likely to respond to immunotherapy if necessary. EGFR, which is a special receptor that some tumors may express that help us use um medications that are usually taken by mouth and, and, and treatment strategies that don't involve traditional chemotherapy in the majority of cases. So it allows us to open up a different avenue of treatment for the patient and, and it tends to be really well tolerated with amazing responses. So um it kind of like opens a new door for that patient. And then the other uh uh marker that tends to be less frequent but it's also important is called ALK. So that tends to be um a receptor that we see in young patients, tends to be uh uh uh that are not smokers usually and that also similar to EGFR we have a targeted therapy or a medication that targets those receptors specifically. That have great clinical results, so we want to make sure that we know that we're not dealing with any of those three scenarios so that we can help the patient choose the right treatment for them. Yes, and I would add that there are other biomarkers, other genes that drive cancer, and now we are having new therapies being approved so quickly, which is amazing because then we are able to offer. Targeted individualized treatment for our patients. So I agree ALC fusions, EGFR mutations is key because we have approved drugs, but we have clinical trials studying other targeted therapies for genes like ROS1, RAT, HER2, so it will keep changing as we continue to move forward and uh like Doctor Bostok mentioned. We need to know this up front because many times Doctor Bostok may call me and say, Doctor Pellini, I need some systemic therapy before surgery, right? And then, uh, surgery will come after. But in other cases surgery will be, uh, the first approach, right? Absolutely. So now, like nowadays I think this, the, uh, the lung cancer space has become so nuanced and so complicated. That it really matters where you go first as a patient. I think that's key for people to understand. If something, if the treatment has been started elsewhere and then we're picking up after the fact, it's difficult to provide the same level of outcomes, right? So where you go first really matters and how you get things done really matters. So we discuss all the time in our In our tumor boards and in our discussions, the sequence of events is critical, right? Some patients, maybe upfront surgery is amazing and that's perfect and that's maybe all they need. Some patients we need to give chemotherapy and immunotherapy before surgery, followed by surgery and maybe more immunotherapy after the fact. Some patients now we're doing. Even in the stage 4 space, you and I discuss this all the time. Sometimes we need to give maybe 2 or 3 months of therapy, reassess. Maybe there's a new role for surgery in those patients. So it's, it's a, it's a conversation that is ever evolving and really here the, the, the, the central message is the sequence of events really matters. So you, you want to make sure you're, you, you're talking to a group that's thinking about this so that you can get the best care as a patient. Yes, and I love that you brought this up. The, the take home message is multidisciplinary care. Nobody should be working in silo nowadays. The surgeons should be working together with the medical oncologists and sometimes we also need help from our radiation oncologists, right? So it's a teamwork, teamwork makes the. DreamWorks. So another thing that we were discussing is the evolving landscape and the new gene alterations that may open the door for different therapies. So I'd like to talk a little bit about KRAS mutations. This has been a hot topic because of pancreatic cancer, and I have done a bit of research in KRAS mutant lung cancer, KRAS G12C mutated lung cancer, and obviously in. Our center we have trials investigating these agents now after surgery and also after chemotherapy and radiation. So this is really the beauty of clinical research. It really opens the door for a new treatment for our patients before approval, right? And that's why it's so important to have this multidisciplinary care where we bring our surgeons to this new era. And work together to achieve the best outcome, right? Yeah, I think having surgeons involved in all of these clinical trials really helps achieve better accrual, maybe better patient selection. Sometimes it even opens up the discussion to challenge the status quo a little bit and start changing what we do, molding this dogma into something more like forward thinking so that more patients get better therapy. So Dr. Bostok, as we continue to develop more effective systemic therapies and explore new approaches to overcoming resistance of cancer genetic alterations, where do you see the greatest opportunities for medical and surgical oncology to work together to improve outcomes? In the last, let's call it 6 years, there's really has been a change in mentality in both medical oncologists and surgical oncologists that deal with lung cancer in, in regards to how we tackle a more advanced disease. So what I'm trying to say is before this time, you used to have patients with stage 1 or stage 2 lung cancer which was mostly a sur uh uh went to surgery and that was about what they got. Uh, then people with stage 3 or stage 4 lung cancer tended to get medical treatment and that's about what they got. Sometimes radiation included into those treatments, uh, but it really depended on each patient and their performance status and things like that. When we started understanding the impact of immunotherapy into this space, then there was a change in mindset. So now, nowadays that standard of care has really shifted. So patients that have stage 2B to 3A lung cancer, and I would probably say stage 3B now, from 2B to 3B really should be offered a multi. Disciplinary evaluation with consideration to do uh to doing perioperative therapy. So what do I mean? Chemotherapy, immunotherapy given before the operation, usually 3 or 4 cycles, most commonly 4, but 3 suffices, followed by surgical resection, followed by immunotherapy, usually for a year. That is our new standard of care, OK? And that really has. Um, opened up the discussion to include a lot of patients that previously were deemed unresectable or not surgical candidates, and suddenly we're seeing really dramatic results. So before the, the, the, the introduction of these treatment strategies, there was a, the, the likelihood of a 5 year survival in a patient with stage 3A was about a third, you know, 35, 36%. And now we're seeing amazing results coming through from these trials where like their 5 year survivals are north of 85% uh with, with, with uh disease free survival, not not only overall survival, so really impactful changes. So that has kind of motivated us to, to challenge the the the this, this environment more. So now that we have all these medications that appear to be so effective, can we do more to debulk the tumor, to get, to control the disease as surgeons, to try to get, get those medications to be more effective and get the patients to live a longer, fuller life. So that's really what's really been changing. Uh, there's new data to suggest that maybe stage 4 as a disease needs to be thought of differently, right? So, um, I, this is an area that I find super fascinating and a lot of my patients have these characteristics where we, uh, classify metastatic disease as a different. Uh, uh, uh, it's not an, not everybody that has metastatic disease should be seen the same, right? So we have people that have widely metastatic disease, meaning there's a bunch of different spots everywhere. The disease is out of control. There's not the, the, the, the, the, the, the, the, the, um. Horizon doesn't look very good. But there's another subset of patients with metastatic disease where they have just a few spots, and we call it oligome metastatic disease or metastatic disease that has just a few spots, usually defined about 3 to 5 spots in the literature. And really the spots do matter for us to make decisions, but what we've learned is that even in people that have metastatic disease to the brain or to the bones or to the adrenal glands. Surgery plays a key role still providing really good outcomes when used in conjunction with perioperative therapy. OK. This is not really the case for people that have, let's see metastatic disease to the pleura or to other organs where it just seems to be more wide, more, more diffuse. So in those patients, it really has changed the conversation because they now get management for their brain lesion. Management for their lung cancer lesion and management for the systemic disease with chemo and immunotherapy with really great results. Yes, I love that you brought this up because there's so many good points and I wanna, uh, repeat some of them. So first of all, uh, patients that have larger tumors or lymph gland involvement, don't be afraid of meeting me or my colleagues and wait for surgery because like Doctor Bosta. It is really important to get some of that treatment before surgery. It does improve clinical outcomes. And the second point is for patients with limited metastatic disease. I think this is a place where we are very innovative at Baptist Health, and we may offer surgical approaches for even patients with stage 4 if they are eligible, depending on. On the area where the cancer is and how many sites are involved, right? So this is very important for patients to know, uh, a lot of patients, they wanna get this more aggressive and innovative treatment. So I love that we're doing that and thank you, Doctor Bostok for being in the forefront of these developments. So now I wanna switch gears a little bit. So I want you to talk to us about robotic. Assisted surgery. This has really expanded our minimally invasive capabilities. So I want you to tell us how has that changed your approach to lung cancer surgery, particularly in terms of precision, recovery, and patient outcomes. Yes, absolutely. So you know a minimally invasive approach to lung cancer has been really In, in vogue since the 90s, but initially we used thoracoscopy or laparoscopy like other people would call it, which makes means small incisions in the chest, but you're standing at the bedside and you're bringing in rigid instruments to try to do the operation. Um this is otherwise known as a VATS procedure or a, or a thoracoscopic procedure. This was invoked for about the, the like the 90s and early 2000s. Um and uh but it, it, it, it's technically it's a little bit more challenging. There's some limitations based on, on, on, on the, the ergonomics of the procedure, the ability to get around difficult structures. Uh, the ability to dissect properly. Of course, there's incredible vet surgeons out there because human beings are gonna, are gonna, uh, uh, thrive in where they dedicate their energy to, right? So of course there's people that are amazing at it, but in general it's more technically challenged, challenging. So then, uh, we started developing a technology towards robotics. So robotic assisted surgery is also. Called thoracoscopy, but instead of standing by the bedside, we dock a special robot with that controls surgical arms that go inside the chest. The robot doesn't do anything by itself. It's all controlled by a surgeon, and the surgeon is typically sit sitting in the same room, but in a console, uh, and is controlling the device for that's doing the operation. Um, uh, really, uh, robotic surgery in my opinion has been a game changer because it allows us to. Uh, do a lot more complex operations than we were doing vats with a lot more precision and usually uh. Comparable to doing an open operation with your hands. So like it really allows you, allows you to get sometimes even better, really close, get around structures that you wouldn't have been able to visualize properly beforehand. So it really has elevated the level of operations that we can provide, uh, and uh with improved outcomes. So we know that, uh, at least from an oncologic standpoint, there's equipoise across all structure uh uh all discipline, all different techniques. So meaning an open operation is just as good as a good vats operation, which is just as good as a robotic operation. But the robotic operation um usually leads to a higher uh yield of lymph nodes, so we're able to dissect the areas around the lung tissue a lot with a lot more precision, so more lymph node yield has been um is usually beneficial so that we can understand what's happening within those lymph nodes. Uh, we know that we tend to convert to an open operation. In a fraction of the cases compared to a vats approach. So what does that mean? That about 3% of cases that started robotically end up needing a bigger incision to finish the operation compared to about 20% with vats. So, uh, so that really translates the idea that what I'm trying to explain is that robotically you're able to get away with a lot more, OK. Um, we have also paired these novel minimal invasive techniques with different, uh, protocols. We call them an enhanced, uh, thoracic surgery protocol or enhanced recovery after thoracic surgery, ERADs. So it really is thinking about different factors that affect the patient experience, including the surgery, but also the anesthetic approach, the, the, the, the pain management. Early mobilization, even nutrition, pre-rehabilitation, all these different concepts so that we can make sure that the patient is doing as well as they possibly can and recover as quickly as possible because we want patients going back to live a full life and not having their surgery impact the quality of that life. Very, very important, and I do want to ask you, usually if there's no. How long do patients stay in the hospital after a robotic assisted surgery? Yeah, so I mean we're a high volume center for robotic surgery, so we do about 90% of our cases robotically at Baptist Health. Most of our patients, it's called that 80 to 90%, go home the next day. The other 10 to 20% may go home the day following. We tend to have short hospital stays, which is excellent. Uh, most of the time within 3 to 4 weeks, the patients are fully recovered and, and going back to living a normal life. Absolutely fascinating. So we're talking about a lung cancer surgery that a patient will go home, many cases, most of the cases within a day or two. This is, uh, life changing and fully recovered after 3 to 4 weeks, so amazing. So now, because there are so many advantages like we just discussed, how do you determine who is an appropriate candidate for this kind of surgery, especially when you are thinking about tumor characteristics. Pulmonary reserve and overall operative risk. Yeah, so I think there's a few things to the points to dissect with that question. Um, so it really from a surgical standpoint, you gotta make sure the patient is fit enough, so a, a, a healthy patient that can undergo surgery, and that doesn't mean the patient needs to be perfectly healthy. Like there's different uh criteria that we use. So we need enough pulmonary reserves so that we can do the operation with single lung ventilation so that we can isolate just one part of the lung. So that, that, so usually the part of the lung that we're working on, we deflate it and we're working on one lung during the operation. So there, there needs to be enough lung function to go through that, right? But enough lung function also that if we were to remove the area that has cancer. The patient usually shouldn't go on to, to need any oxygen, feel short of breath or have have much impact in their quality of life. There may be a little shortness of breath as they recover from surgery for a few weeks, but that should go away and we should expect a full recovery. That's usually the patient that we're talking about, um, and. Really from a surgical standpoint, we look at the anatomy of where and the location of the tumor very carefully. OK, so usually patients that have tumors in the periphery or in the outer third of the lung tissue that have lesions of less than 2 centimeters without any lymph node. Involvement on their PET scan or on their endobronchial ultrasound, we tend to consider them for a parenchymal sparing approach. So that usually means that we're trying to preserve as much lung tissue as possible. Uh, so, uh, that, the, the operation of choice there is either a segmentectomy or a wedge resection. Segmentectomy tends to be favored by me because I think it's a little bit more complete than a wedge resection. But basically what that means is we're taking the anatomic segment where the lung nodule is with a margin of healthy lung tissue, OK, as well as all the lymph nodes that drain the area. Uh, by protocol, we tend to evaluate the lymph nodes in the mediastinum and the hidum very thoroughly, OK, so the more lymph nodes the better because it allows us to fully rule out any involvement with, with, with metastatic disease. One can say, OK, but you did an endobronchial ultrasound and a PET scan, and they were negative. And I'm like, yes, but still within a perfect world with all the technology that we have now, we sometimes can find occult or surprise metastatic disease in those lymph nodes in up to 10 to 25% of cases. So we're super thorough about removing those. So that really takes care of the smaller nodules. So what about nodules? Uh, between the 2 and 3 centimeters, those patients tend to get a lobectomy, which I don't want it to be misconstrued as a, as a lesser operation. It is the standard of care, OK? So removing the lobe where that lung nodule is, OK, uh, usually very safe and, and, and again associated with excellent outcomes. When we start seeing lesions that are bigger than 4 centimeters entering into the stage 2B space, we tend to think. How can we make it smaller? OK. Uh, that doesn't mean that removing it at that time is gonna lead to a specific high risk of complications, but we know that from an oncologic standpoint, patients will do better with a combination approach of what we were talking about before, perioperative therapy, so chemotherapy and immunotherapy to shrink the tumor followed by surgery. So stage 2B to 3B at, at, at Baptist Health South Florida, we tend to recommend. Doing uh new adjuvant therapy. Very good. And now I wanna go into a little bit of your research. So I know you have looked into disparities in access to thoracic surgery. So where are we seeing the greatest barriers, particularly here. In South Florida when it comes to access to surgery and what can we do as physicians to help close those gaps, I think one gap that we constantly run into issues with is are we providing the standard of care. It sounds like a super simple, simple statement, but are we doing the right thing at the right time with the right patient? So I think that really boils down to quality. So we want to, in, in our program we really focus about meeting all these quality land landmarks. So are we, uh, uh, are we providing the right operation for the right patient with the proper staging in the right combination of things so that we. Can get that sequence right, OK? And it would surprise the public and most doctors to say that not every time are we doing the right thing for these patients. So that's a major thing that we, that we could do better at is making sure that that when a patient comes in with a potential diagnosis of lung cancer, we're doing things based on standard of care. We're getting it, we're we're diagnosing it properly. We're staging the media. or making sure we know what's going on with these lymph nodes. When we move on to surgery, are we choosing the right operation? Are we getting a good margin, meaning being far enough far away enough from the tumor that the tumor may not come back? Are we taking enough lymph nodes to make sure that they're not, they don't meet criteria for more therapy? All of those things are fascinating questions that like sound simple enough, but this is how we evaluate ourselves because. It is in the process of evaluating the quality of the program that we make it better. Yes, absolutely, and I'd like to add that we work with community outreach to reach all patient populations and I know you have done some work. I have done some work in the past. This is also critical, but I love how you have always reminded us that it's not only the lung nodule that is. Inside the tissue of the lung, but the lymph glands that drain that area, how important they are, because we see sometimes patients that might have had an operation in a place where the surgeons are not highly specialized like you are and the lymph nodes weren't taken care of and then it's not a proper surgical care for that patient, right? You have to include the lymph nodes. Yes, the lymph nodes really help you understand whether there's more treatment indicated and and you can use the yield of lymph nodes to really judge the quality of that of that resection or or that surgery. So there's things that really like if you read between the lines you gotta make sure that margins are appropriate that the that the lymph node yield is appropriate in order to call something oh this was surgically resected in a proper way. Very good, thank you for sharing this and explaining. I learned so much from you, so I'm very grateful. So to wrap this up, as we look ahead, Doctor Bostok, what is the one message you would want referring physicians and other specialists to take away from today's conversation about lung cancer care or benefit from it? I think it's really important for referring providers and other doctors to understand just how complicated the lung cancer environment has become and, and how nuanced the decision making is. So really relying on a multidisciplinary team to take care of uh of a patient is, is, is quite meaningful. Um, there's even descriptions in the literature of of comparing multidisciplinary treatment compared to community treatment leading to even in upwards of 10% improvements in overall survival. So it's really critical that patients go to the right place at the right time. And I think another key message is uh talking about the sequence of events. So, um, understanding when to provide different therapies and in which order is very important because it can impact the outcome that we can deliver to that patient. And the overall survival and other things that we're looking for. So, um, where you go first matters and the sequencing of events is critical. Well, thank you so much for all the amazing answers to our questions and for really uh teaching us about it. So today's conversation highlighted how rapidly lung cancer care is evolving from advances in screening and diagnostic precision to molecular profiling, targeted therapies, and minimally invasive surgery. We explored how these innovations are changing clinical decision making, creating new opportunities for personalized treatment, and reinforcing the importance of collaboration between medical and surgical oncology. For physicians, the message is clear identifying patients earlier, understanding the biology of their disease, and connecting them with multidisciplinary expertise can make a meaningful difference in their treatment. Options and outcomes to learn more about Baptist Health and our comprehensive cancer center, visit baptisthealth.net. Thank you, Doctor Bostok for sharing your expertise and for the important work you're doing to advance thoracic care. I'm Doctor Bruna Pellini. Thank you for joining us today. To find out more about the topics covered on BaptistHealth.com, please visit physicianresources.baptisthealth.net. Created by